Lumbar degenerative disease
Conditions
Interventions
Esketamine group:Esketamine 0.25 mg/kg IV for induction. Continuous infusion at 0.1 mg/kg/h for maintenance until the end of surgery. Other anesthetic management performed according to standard practi
Normal saline group:IV injection of an equivalent volume of normal saline for induction. Continuous infusion of normal saline at the same infusion rate (volume-matched) as the esketamine group. Other
Sponsors
Taizhou People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Age 50–75 years; 2.ASA physical status classification I–III; 3.Scheduled to undergo posterior lumbar interbody fusion (PLIF); 4.Able to understand and complete the scale assessments.
Exclusion criteria
Exclusion criteria: 1.Allergy to ketamine, esketamine, or other study-related medications; 2.Severe cardiovascular disease; 3.Severe hepatic or renal dysfunction; 4.Cognitive impairment or psychiatric disorders; 5.Presence of glaucoma, adrenal diseases, or hyperthyroidism; 6.Long-term preoperative use of anxiolytics, antidepressants, or hypnotics; 7.Preoperative assessment indicating severe anxiety or severe depression.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative HADS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Richards-Campbell Sleep Questionnaire;Visual Analogue Scale;Effective presses of patient-controlled analgesia within 24 hours after surgery;PACU observation time and analgesic consumption;Intraoperative and postoperative adverse events, such as nausea and vomiting, abnormal heart rate/blood pressure, and psychiatric symptoms (hallucinations, illusions, agitation), etc.; | — |
Countries
China
Contacts
Public ContactLin Jiang
Taizhou People's Hospital
Outcome results
None listed